We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Flags Concerns on Widening Cancer Drug Trial Eligibility Criteria
Merck Flags Concerns on Widening Cancer Drug Trial Eligibility Criteria
Merck urged the FDA to look into potential safety concerns as the agency seeks to widen patient eligibility criteria for oncology drug trials of HIV, hepatitis B and hepatitis C patients.